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Available online 21 November 2015AbstractSarcopenia is a progressive and generalized loss of muscle mass and either a loss of muscle strength or physical performance. Its prevalence
increases with age and is associated with multiple unfavorable clinical outcomes. The operational definitions and diagnostic strategy of sar-
copenia in Asia is currently based on the consensus of the Asian Working Group of Sarcopenia (AWGS) which requires measurements of muscle
mass, muscle strength, and physical performance. This article reviewed the epidemiology, impact, pathophysiology, recommended tools and
their cut-offs for diagnosis of sarcopenia in Asia according to the consensus of the AWGS and existing evidence in Asia. It is clear that exercise,
diet and nutrition are beneficial for sarcopenic adults in the areas of prevention and treatment but no medications are currently proven. Future
study in Asia should be straight forward to include intervention for prevention and treatment of sarcopenia.
© 2015 The Korean Society of Osteoporosis. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sarcopenia, a new geriatric syndrome, is an aging-related
condition defined by a progressive and generalized loss of
muscle mass and function defined as muscle strength and/or
physical performance [1,2]. Sarcopenia has emerged as one of
the most common problems in the elderly population and is
representative of one of the most significant public health
concerns since it can accelerate to the frailty syndrome [3]
resulting in adverse clinical outcomes and health status, i.e.,
physical impairment and disability, poorer quality of life,
increased risk of falls, hospitalization, morbidity, mortality
and health care costs [4e10].
Over the past two decades after the term “sarcopenia” was
introduced by Rosenburg [11], the research in sarcopenia has
been investigated extensively including pathophysiology, risk* Corresponding author. Tel.: þ66 43 363664; fax: þ66 43 202491.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).factors, criteria for diagnosis, consequences of sarcopenia and
therapeutic options. Due to the escalation of the elderly pop-
ulation worldwide and especially in Asia, the importance of
prevention and early detection of individuals with sarcopenia
is crucial.2. Epidemiology of sarcopenia in Asia
In general, a progressive loss of muscle mass occurs at the
age of 40 at the rate of 8% per decade and increases to 15%
per decade after 70 years [12]. For muscle strength, it declines
10e15% per decade and more rapidly after the age of 70 years
[12]. A longitudinal study of muscle mass, grip strength and
gait speed change over 4 years in a community setting of older
Chinese showed that these older Chinese had less muscle
mass, weaker grip strength and slower gait speed than black or
white people of the same age. The decline of gait speed and
grip strength was faster than muscle mass but the decrease of
grip strength in Chinese women was especially notable [13].
The prevalence of sarcopenia in Asia was different amongElsevier B.V. This is an open access article under the CC BY-NC-ND license
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populations and measurement methods. There is inconsistent
prevalence of sarcopenia in Asian populations [3,12,14]. The
prevalence; however, was higher with advancing age and
higher in men than in women in most studies. Additionally,
persons with a low body mass index and who lived in nursing
homes had a higher prevalence of sarcopenia [15]. The studies
in older Chinese communities found that being under weight,
advancing age, cigarette smoking, chronic obstructive pul-
monary disease (COPD), atherosclerosis and physical inac-
tivity were associated with sarcopenia [16,17] whereas the one
study in Thailand showed that apart from advancing age, an
urban environment and high body mass index were the pre-
dictive factors for sarcopenia [18].
The studies regarding sarcopenia in Asia are fewer than the
studies in Europe and America. Existing Asian studies were
conducted in Japan, China, Taiwan, Korea and Thailand. The
prevalence of sarcopenia based on low muscle mass alone is
greater than the current definition which required either low
muscle strength or poor physical performance. Asian people
appear to have a higher prevalence of sarcopenia than other
regions [15]. Its prevalence in older adults according to low
muscle mass in Asia varied from 6.7 to 56.7% in men and
0.1e33.6% in women [14,16] whereas the prevalence ac-
cording to the current definition is 9.6e22.1% in men and
7.7e21.8% in women [14,15]. The prevalence of sarcopenia
using only low muscle mass in diabetic patients in the Korean
Sarcopenic Obesity Study (KSOS) was 15.7% and found that
diabetes was an independent factor associated with sarcopenia
[19]. Setting uniform criteria among Asian countries and using
optimal cutoff points for individual ethnicities would be
worthwhile for further studies regarding the impact and
appropriate management of sarcopenia.
3. Impact of sarcopenia
The impacts of sarcopenia are the results of intrinsic cau-
ses; physiologic change of ageing and extrinsic causes that
lead to increased metabolic demands such as chronic illness,
lifestyle behavior and medication use. Consequently, physical
inactivity occurs and accelerates frailty. Several public health
burdens are evidenced accordingly including physical
disability, falling, nursing home admission, hospitalization,
depression, poor quality of life, increased health care expen-
ditures, poor physical performance, adverse metabolic effects
and even mortality [12,14,20].
Sarcopenic patients had a worse functional status than non-
sarcopenic patients. One report showed that older patients
from subacute geriatric wards with sarcopenia had a negative
impact on their functional status during hospitalization and
even at 3-month follow-ups than the patients without sarco-
penia [21]. It indicates the impairment in activities of daily
living, gait speed or regularity [15]. A study in older Japanese
showed that the prevalence of sarcopenia was greater in per-
sons who had a history of falling with the odds ratio of 4.42
(95%CI 2.08e9.39) in men and 2.34 (95%CI 1.39e3.94) in
women [22]. A prospective study in sarcopenic older adultsaged 80 years or over showed an increased mortality inde-
pendent of age and other clinical and functional variables with
the hazard ratios (HR) of 2.32, 95%CI: 1.01e5.43 [23].
Additionally, sarcopenia is associated with several comor-
bidities including osteoporosis and possibly increases fracture
risk via crosstalk between muscle and bone tissues and esca-
lates the falling risk [15]. The presence of atherosclerotic-
related diseases such as hypertension, diabetes, cardiovascu-
lar disease (CVD), chronic kidney disease is also associated
with sarcopenia particularly in patients with sarcopenic
obesity [15,24e26]. Japanese studies also found that the as-
sociation between sarcopenia and cardiovascular disease was
not dependent on the waist circumference, age and body
composition [26,27]. One study in Korea reported that the
women with sarcopenic obesity and even sarcopenia without
obesity had three times and twice the risks of developing
metabolic syndrome than normal subjects. The similar trend
was also found in men [28,29].Arterial stiffness, especially in
the female, is associated with sarcopenia as shown in Korean
and Japanese studies [25,26]. The possible mechanisms are
insulin resistance since muscle loss causes a reduced insulin-
responsive target tissue, inflammatory processes, reduced
myokines and a change in the renin-angiotensin-aldosterone
system (RAAS) that may promote CVD risks and a derange-
ment of other metabolic profiles [24,25]. Furthermore, hypo-
gonadism and hypercortisolism is also associated with
sarcopenia independent of age under the mechanism of
physical disability [15].
4. Pathophysiology
There are several proposed mechanisms of sarcopenia that
can be classified as primary or age-related sarcopenia. It is
associated with sex hormones, apoptosis and mitochondrial
dysfunction, anorexia of ageing, and secondary sarcopenia
including 1) neurodegenerative processes such as motor
neuron diseases, 2) endocrinopathy which is associated with a
reduction of anabolic hormone levels, eg. growth hormone,
insulin like growth factor-1 (IGF-1), testosterone, vitamin D,
increased cortisol, abnormal thyroid function and insulin
resistance, 3) pro-inflammatory cytokines that are interleukin-
1, interleukin-6 and tumor necrosis factor-alpha, 4) inadequate
nutrition or malabsorption and 5) disuse situations such as the
immobilization syndrome, physical inactivity and persons with
zero gravity [3,12,30,31] (Fig. 1).
5. Definition
Currently, operational definitions and diagnostic strategy of
sarcopenia in Asia is based on the consensus of the Asian
Working Group of Sarcopenia (AWGS) which was modified
from the European Union Geriatric Medicine Society
(EUGMS) and the European Working Group on Sarcopenia in
Older People (EWGSOP). The diagnosis requires measure-
ments of muscle mass, muscle strength, and physical perfor-
mance. It is; however, different in measurement of both
muscle strength and physical performance as the screening
Fig. 1. Summary of pathogenesis of sarcopenia [30]. GH: growth hormone,
IGF-1: insulin like growth factor-1.
Table 1
Measurement tools and recommend cutoff values in clinical practice.
Measurement Tools Cutoff values
Men Women
Muscle massa Dual energy X-ray
absorptiometry; DXA
7 kg/m2 5.4 kg/m2
Bioimpedance analysis (BIA) 7 kg/m2 5.7 kg/m2
Muscle strength Handgrip strength (HS) 26 kg 18 kg
Knee flexion/extension
(quadriceps strength)
18 kg 16 kg
Physical performance 6-m usual gait speed 0.8 m/s 0.8 m/s
a Relative appendicular skeletal mass/height [2,14].
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on the existing studies in Asian societies. Ethnicities, body
sizes, lifestyle, and cultural background can influence the
different cutoff values [4,14,32]. Severities of sarcopenia are
classified into 3 groups for targeted plans of management;
presarcopenia, sarcopenia and severe sarcopenia. Pre-
sarcopenia is defined as a presence of low muscle mass only,
sarcopenia is diagnosed when there is a presence of low
muscle mass and either low muscle strength or low physical
performance, and severe sarcopenia is defined as when pre-
senting low muscle mass, low muscle strength and low
physical performance are apparent [30].
There are several assessment tools to measure muscle mass,
muscle strength and physical performance. Tools that used to
measure muscle mass are 1) body imaging techniques;
computerized tomography (CT scan), magnetic resonance to-
mography (MRI), and dual energy X-ray absorptiometry
(DXA), 2) bioimpedance analysis (BIA), 3) potassium per fat-
free soft tissue measurement, and 4) anthropometric measures.
The commonly used and feasible tools are DXA and BIA.
Muscle strength measurement includes handgrip strength
(HS), knee flexion/extension (quadriceps strength), and peak
expiratory flow (PEF). Physical Performance Battery (SPPB),
usual gait speed, timed get-up-and-go test (TGUG), and Stair
climb power test (SCPT) are measurement tools of physical
performance. There are; however, some limitations of those
tools in clinical practice including the availability, feasibility,
cost, and optimal cutoff values. Recommended tools and their
cutoff values in Asia according to the consensus of the AWGS
and existing evidence in Asia are shown in Table 1
[14,20,30,32e34].
According to the recommendation of the AWGS [14], all
older adults at the age of 60 or 65 or over, depending on
definition of older adults in each country, in the community
setting should be screened for sarcopenia. Case findings
should be performed in at-risk persons including 1) presence
of recent functional decline or functional impairment, 2)unintentional body weight loss over 5% in a month, 3)
depressive mood or cognitive impairment, 5) repeated falls, 6)
undernutrition, and 7) chronic conditions such as chronic heart
failure, chronic obstructive pulmonary disease, diabetes mel-
litus, chronic kidney disease, connective tissue disease,
tuberculosis infection, and other chronic wasting conditions.
The algorithm of sarcopenia diagnosis presented by AWGS is
demonstrated in Fig. 2 [14].
6. Management
It is clear that non-pharmacological management is bene-
ficial for sarcopenic adults in the areas of prevention and
treatment i.e. exercise, diet and nutrition. No medications are
currently proven to be as efficacious as exercise but they might
reduce functional decline in older adults in deficiencies such
as testosterone, dehydroepiandrosterone (DHEA), growth
hormone (GH) and vitamin D [3,15,20,35e37].
1 Exercise: physical inactivity is part of the mechanisms of
sarcopenia. Therefore, exercise can reverse or prevent the
occurrence of sarcopenia. Exercise appears to be the most
effective method to improve quality of life and function in
older adults even in the very elderly or frail adults [38].
Resistance exercise (RE) is the type of exercise that
mainly increases muscle mass and muscle strength by
directing stimulation of protein synthesis particularly by
progressive resistance exercise (PRE) which is the most
common use of resistance therapy. It requires muscle to
generate power to move or resist weight and escalate the
intensity when physical capacity improves [31,38,39]. A
meta-analysis and systematic review showed that PRE
could reduce physical disability in older adults [36,40].
Aerobic exercise is type of exercise that benefits improved
cardiovascular fitness and increased endurance. It in-
creases the cross-sectional area of muscle fibers, mito-
chondrial volume and enzyme activity; however, it is less
likely to increase muscle hypertrophy [38,41]. Combina-
tions of aerobic and resistance exercise can further
improve muscle strength and muscle function and is
important to prevent and treat sarcopenia [38,41,42].
2 Diet: anorexia of ageing is the commonly used word to
define reduced appetite and low intake in the elderly.
Fig. 2. Algorithm of sarcopenia diagnosis presented by AWGS. AWGS: Asian
Working Group of Sarcopenia.
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nent of established sarcopenia. Older adults usually intake
less protein than the daily recommendation [12,35]. It can
be the result of physiologic change, economic limitation
and comorbidities. Furthermore, anabolic resistance oc-
curs in the elderly due to the decline in insulin-like growth
factor-I (IGF-I) levels in older adults relative to young
adults causing blunting of the response of muscle protein
synthesis [12,35]. Therefore, the daily recommendation of
protein in older adults, if no contraindication is present, is
about 1.5 g/kg/day which is higher than current recom-
mended dietary allowance (RDA) of protein and should
distribute protein intake throughout the day [35,38]. The
essential amino acid (EAA) leucine is the most important
protein component that plays an important role for muscle
protein synthesis and declined proteolysis. Encouraging
older adults to intake adequate protein with a high rich-
leucine diet such as beef, fish and legumes is advised [35].
Vitamin D decreases with age as a result of intrinsic change
in vitamin D synthesis and extrinsic causes eg. malnutrition
and reduced sunlight exposure in older adults particularly
in frail elderly [43,44]. It is indicated in osteoporosis and
vitamin D deficiency but the role for sarcopenia is limited
[39]. Vitamin D deficiency is related to altered muscle
morphology causing osteomalacia and myopathy, reduced
muscle strength, muscle mass and physical performance
and bone mineral density that leads to an increased risk of
falling and fracture as reported in observational studies and
meta-analysis [43]. Vitamin D supplementation; however,
does not show beneficial effects in improved muscle
strength, muscle function and decreased risk of falls and
fracture but co-administration with 1000 mg of calcium in
vitamin D deficient patients can decrease this risk of falling
[43]. This effect is dose-dependent (700e1000 IU/d of
vitamin D3) and vitamin D level of at least 60 nmol/L is
required for fall and fracture prevention in community-
dwelling older adults [35,43,45e47].
There is evidence that a combination of exercise and
adequate dietary supplementation is superior to exercisealone for increased muscle strength, muscle mass and gait
speed in sarcopenic patients. Therefore adequate energy
and protein intake during exercise is important [48e50].
3. Medications: the mechanisms of pharmacological man-
agement of sarcopenia focus on various pathways such as
androgen receptors, peroxisome proliferator-activiated re-
ceptor-gamma coactivator 1-alpha, myostatin, peroxisome
proliferator-activated receptor-delta, insulin-like growth
factor 1, beta-adrenergic receptors, neuregulins,
angiotensin-converting enzyme, and inflammatory cyto-
kines. There is; however, no drug proven for use in sarco-
penia for prevention and treatment at present. Some
medications improved muscle mass, muscle function and
physical performance in animal studies but there are rela-
tively small trials in older adults. The adverse effects of
pharmacological use are also the limitations of prescribing
thesemedications. New future drugs that improve functional
decline in older adults are of interest. Most studied drugs are
testosterone, GH, DHEA and vitamin D [39,51,52].
Testosterone is an anabolic hormone that is currently
indicated in persons with androgen deficiency. It can
improve muscle mass, reduce fat mass, but the benefit in
improvement of muscle strength is insufficient to recom-
mend its use due to the methodological issues. High dose
testosterone increased contraction force in older adults. In
addition, testosterone is associated with prostate cancer,
increased cardiovascular risk, exacerbates sleep apnea,
transient fluid retention, gynaecomastia, aggressive
behavior, and increased red cell mass which contradicts its
use in older adults [37,39,53].
Growth hormone (GH) treatment is indicated in growth
disorders and growth hormone deficiency. The benefits of
GH in older adults are associated with increased total lean
body mass, decreased fat mass and decreased bone dem-
ineralized rate but the role in increased muscle strength,
muscle power, aerobic endurance and physical perfor-
mance after short treatment periods is limited. Severe side
effects are also found including joint pain, carpal tunnel
syndrome, edema, carbohydrate intolerance, diabetes and
tumors [39,51,54].
Dehydroepiandrosteron (DHEA) is a precursor of sex
hormones and indicated in testosterone deficiency. It can
increase bone density in older adults and it is hypothesized
that it can increase muscle strength via an increased ratio
of circulating testosterone to cortisol. In human studies,
the effects in increased muscle mass, muscle strength and
muscle function were questionable. Therefore, it cannot be
recommended for use in sarcopenic patients [36,39].7. Future research in Asia
There is growing research regarding sarcopenia in Asia.
Most studies have been conducted in East Asia but ethnicities,
cultural backgrounds and body sizes can influence the preva-
lence of sarcopenia. Other parts of Asia are, therefore,
encouraged to focus on this area. Studying should be directed
96 P. Limpawattana et al. / Osteoporosis and Sarcopenia 1 (2015) 92e97to prevention and treatment of sarcopenia using exercise or
dietary programs that are suited to the lifestyles of Asian
populations. Early recognition of this new geriatric syndrome
is also very crucial for detection and novel studies should pay
attention to identifying the associated factors that underlie
mechanisms of sarcopenia which can be modified prior to
established sarcopenia.
8. Conclusion
Sarcopenia is one of the geriatric syndromes that increases
with age and is associated with numerous adverse outcomes.
The prevalence of sarcopenia in Asia is diverse due to the
differences in its definition and methodological studies. Older
adults or high risk persons should be screened for this con-
dition. Exercise especially PRE and adequate nutritional
support are the key components of management. To date, an
unclear benefit of medications for treatment of sarcopenia is
noted. Future study should be straight forward to include
intervention for prevention and treatment of sarcopenia.
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